Research Article
Prognosis and Prognostic Factors of Serous Borderline Tumor-Micropapillary Variant: Retrospective Study of 200 Patients with Long-Term Follow-Up
Table 1
Demographic and clinical features of the patients with SBOT-Ms (N = 200).
| | Parameters | Overall cohort, (%), | Radical group, (%), | Conservative group, (%), | value |
| | Age (median, range, years) | | 32 (17-68) | 42 (20-68) | 28 (17-42) | <.001 | | Age, years † | ≤ 35 | 125 (62.5) | 22 (28.2) | 103 (84.4) | <.001 | | > 35 | 75 (37.5) | 56 (71.8) | 19 (15.6) | | | Nulliparous | Yes | 108 (54.0) | 20 (25.6) | 88 (72.1) | <.001 | | No | 92 (46.0) | 58 (74.4) | 34 (27.9) | | | CA-125 (median, range, U/mL) | | 210 (5.6-25000.0) | 284.3 (5.6-25000.0) | 175 (7.1-12313) | .346 | | Referral | Yes | 64 (32.0) | 21 (26.9) | 43 (35.2) | .218 | | No | 136 (68.0) | 57 (73.1) | 79 (64.8) | | | Surgical approach | Laparotomy | 134 (67.0) | 69 (88.5) | 65 (53.3) | <.001 | | Laparoscopy | 66 (33.0) | 9 (11.5) | 57 (46.7) | | | Complete staging | Yes | 127 (63.5) | 74 (94.9) | 53 (43.4) | <.001 | | No | 73 (36.5) | 4 (5.1) | 69 (56.6) | | | Lymphadenectomy | No | 140 (70.0) | 30 (38.5) | 110 (90.2) | <.001 | | Yes | 60 (30.0) | 48 (61.5) | 12 (9.8) | | | Ovarian involvement | Unilateral | 63 (31.5) | 17 (21.8) | 46 (37.7) | .018 | | Bilateral | 137 (68.5) | 61 (78.2) | 76 (62.3) | | | FIGO stage | I | 106 (53.0) | 28 (35.9) | 78 (63.9) | <.001 | | II-IV | 94 (47.0) | 50 (64.1) | 44 (36.1) | | | Stromal microinvasion | No | 164 (82.0) | 55 (70.5) | 109 (89.3) | .001 | | Yes | 36 (18.0) | 23 (29.5) | 13 (10.7) | | | Type of implants () | Noninvasive | 68 (72.3) | 34 (68.0) | 34 (77.3) | .316 | | Invasive | 26 (27.7) | 16 (32.0) | 10 (22.7) | | | Adjuvant chemotherapy | No | 146 (73.0) | 42 (46.2) | 104 (85.2) | <.001 | | Yes | 54 (27.0) | 36 (53.8) | 18 (14.8) | |
|
|
Values are (%) unless stated otherwise. †Based on X-tile analysis. |
